Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, bone marrow disorder, disease, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myeloid leukemia, neoplasm	Recruiting	Phase 1 / Phase 2	2026-09-01		NCT05322850

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Orca Biosystems, Inc.	8
University of Florida	315

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Johns Hopkins All Children's Hospital	St. Petersburg	United States	116
Nicklaus Children's Hospital	Miami	United States	112
University of Florida	Gainesville	United States	70
University of Miami	Miami	United States	327